FDA expands approval of Imfinzi to reduce the risk of NSCLC progression.
The FDA has approved Imfinzi for the treatment of patients with stage III non-small cell lung cancer whose tumours are not able to be surgically removed and whose cancer has not progressed after treatment… The US Food and Drug Administration has approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung